PDF / 60 KB 
collectBayerNews_20090708_0282_en.pdf BayerNews_20090708_0282_en.pdf
FDA approval requested for oral contraception and treatment of heavy and/or prolonged menstrual bleeding
Berlin, July 8, 2009 - Bayer has submitted a New Drug Application (NDA) to the
U.S. Food and Drug Administration (FDA) for a new estradiol-based oral
contraceptive (estradiol valerate/dienogest). It seeks approval for the
indications oral contraception and treatment of heavy and/or prolonged
menstrual bleeding. The new product with an estradiol valerate/dienogest
combination is the first in a new class of oral contraceptives to deliver
estradiol, the estrogen identical to the one produced by the female body. It is
marketed in Europe under the tradename Qlaira®.
"We are pleased to be able to submit the NDA for this new estradiol-based oral
contraceptive in the U.S. only a few weeks after Qlaira's launch in Europe,"
said Phil Smits, M.D., Head of Women's Healthcare at Bayer Schering Pharma. "We
see a high interest in this new oral contraceptive by women and gynecologists.
The NDA underscores the culmination of years of research and development that
confirms our goal of developing innovative products that deliver benefits
beyond reliable contraception."
Over the past 50 years, many new progestins have been developed for use in oral
contraceptives, but the estrogen component remained the same -
ethinylestradiol. The new oral contraceptive contains the combination of
estradiol valerate - which is immediately metabolized to estradiol, equivalent
to the estrogen as produced by a woman's ovaries - with the progestin dienogest
in a unique dosing regimen. This dosing regimen has been designed to deliver
hormones at the right levels at the right time during the cycle. If approved by
the FDA, the introduction of this new product will offer women a new choice in
oral contraception.
An approval for the additional indication - treatment of heavy and/or prolonged
menstrual bleeding in the absence of organic pathology in women who desire oral
contraception - would represent another important milestone. No other oral
contraceptive has yet been approved for treating this condition.
The new oral contraceptive has been available under the tradename Qlaira since
May 2009, in several European countries, for the indication oral contraception.
Additional European countries will launch Qlaira in autumn 2009 . Bayer is
planning to submit the indication heavy and/or prolonged menstrual bleeding in
Europe in 2010.
About Bayer
The Bayer Group is a global enterprise with core competencies in the fields of
health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary
of Bayer AG, is one of the world's leading, innovative companies in the
healthcare and medical products industry and is based in Leverkusen, Germany.
The company combines the global activities of the Animal Health, Bayer Schering
Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare's aim is to
discover and manufacture products that will improve human and animal health
worldwide. Find more information at www.bayerhealthcare.com.
About Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company.
Its research and business activities are focused on the following areas:
Diagnostic Imaging, General Medicine, Specialty Medicine and Women's
Healthcare. With innovative products, Bayer Schering Pharma aims for leading
positions in specialized markets worldwide. Using new ideas, Bayer Schering
Pharma aims to make a contribution to medical progress and strives to improve
the quality of life. Find more information at www.bayerscheringpharma.de.
